Navigation Links
Medication appears well-tolerated, beneficial in Huntington's disease patients
Date:2/8/2010

A medication previously studied in patients with Alzheimer's disease (latrepirdine) appears well tolerated and may improve thinking, learning and memory skills among individuals with Huntington's disease, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals.

"Huntington's disease is a hereditary neurodegenerative disorder that affects movement, behavior and cognition and leads to death within 20 years of disease onset," the authors write as background information in the article. "Cognitive [thinking, learning and memory] impairment occurs early in the disease and deteriorates as Huntington's disease progresses, contributing to loss of ability to work and perform activities of daily living." The only approved therapy for Huntington's disease, tetrabenazine, treats only motor symptoms and does not alter the course of the disease or prevent cognitive decline.

Abnormalities in mitochondria, parts of cells that help convert food into energy, have been implicated in the development of Huntington's disease. The synthetic molecule latrepirdine stabilizes and improves mitochondrial function, and has been studied as a way to improve cognitive, behavioral and functional outcomes in patients with Alzheimer's disease. Karl Kieburtz, M.D., M.P.H., of the School of Medicine and Dentistry, University of Rochester, N.Y., and colleagues assessed the safety and tolerability of latrepirdine among 91 participants with mild to moderate Huntington's disease at enrollment (2007 to 2008).

For 90 days, 46 patients were randomly assigned to take 20 milligrams of latrepirdine three times daily and the other 45 took a matching placebo. The medication was well tolerated (87 percent of the patients given latrepirdine completed the study, compared with 82 percent in the control group) and adverse event rates were similar between the two groups (70 percent in the treatment group vs. 80 percent in the placebo group).

In addition, the treatment resulting in improved average scores on an evaluation measuring overall cognitive function. Scores of individuals in the placebo group remained steady over the study period.

"Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," the authors conclude. "Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease."


'/>"/>

Contact: Abena Foreman-Trice
abena@virginia.edu
434-243-2734
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
2. Manic phase of bipolar disorder benefits from breast cancer medication
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Mayo Clinic study indicates medication for ADHD may help student outcomes
5. Diet and medications may assist prevention of prostate cancer
6. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
7. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
8. Moses Taylor Hospital Automates Medication Reconciliation
9. Cautious Optimism for New Alzheimers Medications, Reports the Harvard Mental Health Letter
10. Patients cant recall their medications to tell doctors
11. Patient Empowerment -- Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Establishment Labs, ... of Dr. David Hung to the company´s Board of Directors. , “We ... class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment ...
(Date:2/9/2016)... ... 09, 2016 , ... ZipHearing.com is proud to ... hearing aids , increase industry transparency, and promote awareness of hearing solutions ... “For the average consumer, the hearing aid industry is esoteric and difficult to ...
(Date:2/9/2016)... ... February 09, 2016 , ... Sir Grout, ... , is proud to announce that many of their franchises have received the ... The hard surface restoration franchises received customer recognition through positive reviews and testimonials, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... its newly redesigned website, federallabs.org . The site houses a wealth of ... available federal technologies through the process called technology transfer (T2). As a network ...
(Date:2/8/2016)... ... ... man who has struggled to quit smoking, a man who has struggled with hair loss ... to his problems – and he did. Now Nabat, a serial entrepreneur featured as the ... inventions to the world and better people's lives. His own experience with nicotine addiction led ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Aesthetic Devices - Medical Devices Pipeline ... report, "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" ... stage. This report is prepared using ... by GlobalData,s team of industry experts. *Note: Certain ... based on the availability and relevance of data in ...
(Date:2/8/2016)... 2016  Ventana Medical Systems, Inc. (Ventana), a member ... world,s top oncologists, pathologists, research scientists and healthcare ... annual Tucson Symposium March 8-9 to learn ... outcomes in cancer research and treatments that will ... Thomas Grogan , annually draws more than 500 ...
(Date:2/8/2016)... LEAWOOD, Kan. , Feb. 8, 2016 ... held organization that formerly specialized in the ... facilities, recently announced that it has divided ... Nueterra Capital. While Nueterra Capital will continue ... advisory services, NueHealth will operate a national ...
Breaking Medicine Technology: